Affiliation:
1. Transplant Immunology and Histocompatibility Laboratory Department of Pathology University of Texas Southwestern Medical Center Texas USA
2. Histocompatibility and Immunogenetics Laboratory Alberta Precision Laboratories Alberta Canada
3. Department of Pathology and Laboratory Medicine University of Calgary Calgary Alberta Canada
4. Department of Medicine University of Calgary Calgary Alberta Canada
Abstract
AbstractBackgroundAntibodies against human leukocyte antigen (anti‐HLA Abs) are associated with an increased risk of allograft loss. Herein, we report the prospective follow‐up for anti‐HLA Abs formation in 103 patients with end‐stage kidney disease on the waiting list for transplantation who underwent COVID‐19 vaccination.Patients and methodsSera were tested before and after vaccination using Luminex technology. The cohort comprised of 62 males and 41 females with a mean age of 56 ± 14 years. The patients received BNT162b2 (80.4%), mRNA‐1273 (18.5%), AZD1222 (0.40%), or ChAdOx1‐S (0.80%) vaccine. Patients were tested before and within 119 ± 50, 95 ± 46 and 25 ± 26 days after the first, second, and third dose of the vaccine, respectively.ResultsNo significant change in calculated panel reactive antibody (cPRA) after vaccination was seen. Although 98.1% of patients had no change in anti‐HLA Abs profile or cPRA after vaccination, two patients (1.9%) developed de novo anti‐HLA Abs against class I or II HLA antigens. In those two patients, the cPRA changed from 0% and 63% at baseline to 9% and 90% after vaccination, respectively. Both patients received the BNT162b2 mRNA‐based vaccine. The earliest detected anti‐HLA Abs was 18 days after the first dose.ConclusionIn rare cases, new anti‐HLA antibodies were observed after COVID‐19 vaccination, with potential implications for transplantation. The low incidence of this phenomenon is outweighed by the clinical benefits of vaccination.
image
Subject
Infectious Diseases,Transplantation